MGUS Trials

Finding and understanding your clinical trial options for monoclonal gammopathy of undertermined significance (MGUS) can be difficult and confusing and that's where we can help. Create an account or call us today and we'll help determine which trials you may be eligible to participate in.

Create Your Account

Create your account today and get matched to eligible myeloma clinical trials.

  • Find clinical trials in your home town or around the country.
  • Find a myeloma specialist.
  • Receive alerts when new trials become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

THE PROMISE study is the first study to test healthy people who may be at risk for early warning signs of a blood cancer called multiple myeloma.

No travel is required to participate in this observational trial.

Learn more about this trial

Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome (PCROWD)

The PCROWD is part of the Center for Prevention of Progression of Blood Cancers (CPOP), a research initiative at Dana-Farber Cancer Institute focused on understanding the progression and clonal evolution of blood cancers, with an ultimate aim to develop targeted therapeutic agents that can eliminate the early clones of disease.

No travel is required to participate in this observational trial.

Learn more about this trial

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life.

No travel is required to participate in this observational trial.

Learn more about this trial

MMRF Molecular Profiling Protocol

The purpose of the Molecular Profiling Initiative (MPI) is to provide timely CLIA genomic sequencing information to MM patients and their doctors, allowing them to make informed treatment decisions and identify potential treatment options based on a patient’s genomic alterations.

Learn more about this trial

Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

This research study is studying Daratumumab as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM).

Learn more about this trial

Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies

The goal of this clinical research study is to find markers that might help predict why some patients with monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) develop multiple myeloma, while others do not.

Learn more about this trial